Biorestorative Therapies (NASDAQ:BRTX) Cut to Hold at Maxim Group

Maxim Group downgraded shares of Biorestorative Therapies (NASDAQ:BRTX) from a buy rating to a hold rating in a research note published on Tuesday, MarketBeat.com reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday, August 24th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Biorestorative Therapies currently has an average rating of “Reduce”.

Biorestorative Therapies Price Performance

Shares of BRTX stock opened at $1.89 on Tuesday. Biorestorative Therapies has a 1 year low of $1.75 and a 1 year high of $34.60. The company’s fifty day simple moving average is $3.34 and its two-hundred day simple moving average is $5.10. The stock has a market capitalization of $2.61 million, a price-to-earnings ratio of -0.09 and a beta of 0.94.

About Biorestorative Therapies

BioRestorative Therapies, Inc (NASDAQ:BRTX) is a development-stage biotechnology company focused on regenerative medicine and cell-based therapies. The company’s programs are designed to use adult stem cells and related biological materials to address conditions for which existing treatment options may be limited.

Its lead program, BRTX-100, is an autologous cell therapy derived from a patient’s own bone marrow. The product is being developed for the treatment of painful chronic lower-back conditions associated with degenerative discs.